The current advanced pipeline includes Androgen Restored Contraception (ARC), Estetrol (E4) and Zona Pellucida (ZP) immunotherapy (antigen immunisation). ZP for ovarian cancer has been sold to HRA Pharma (France) in October 2014, whereas the other applications were retained by PRB. All rights on E4 have been sold to Mithra Pharmaceuticals (Belgium) in March 2015, whereas PRB has exclusively licensed back the rights on oncological and veterinary applications. PRB has founded a subsidiary company – Pantarhei Oncology (PRO) – to develop oncological treatments with a current focus on breast and prostate cancer.

Androgen Restored Contraception (ARC)
E4 - Oncology
E4 - Veterinary use
ZP - Immunization



Pre-clinical / GLP-tox


Clinical / Phase I


Clinical / Phase II


Clinical / Phase III